Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2003 12:00 ET | Source: Novuspharma SpA

Novuspharma SpA Announces Financial Results for the Six Months Ended 30 June 2003

MILAN, Italy, August 7, 2003 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato:NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the six months ended 30 June...
July 07, 2003 02:05 ET | Source: Novuspharma SpA

Novuspharma SpA -- Novuspharma's Pixantrone Regimen Produces High Response Rates In Relapsed Aggressive Lymphoma

BRESSO, Italy, July 7, 2003 (PRIMEZONE) -- Novuspharma SpA (Other OTC:NVUSF) (Nuovo Mercato: NOV.MI and NOV IM), a biopharmaceutical company focused on developing new cancer therapeutics, today...
February 28, 2003 12:30 ET | Source: Novuspharma SpA

Novuspharma SpA Announces Financial Results for the Twelve Months ended December 31, 2002

MONZA, Italy, February 28, 2003 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato:NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the twelve months ended...
November 13, 2002 14:18 ET | Source: Novuspharma SpA

Novuspharma SpA Announces Financial Results for the Nine Months Ended September 30, 2002

BRESSO, Italy, Nov. 13, 2002 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato: NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the nine months ended 30...
May 15, 2002 04:55 ET | Source: Novuspharma SpA

Novuspharma SpA Announces Financial Results for the First Quarter Ended March 31, 2002

BRESSO, Italy, May 15, 2002 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato: NOV.MI) (ISIN:IT0001482444), a biotechnology company focused on cancer, today announced financial results for the first...
May 15, 2002 04:01 ET | Source: Novuspharma SpA

Novuspharma Acquires Rights to Anti-Angiogenesis Research Program from Prolifix

BRESSO, Milan and OXFORD, U.K., May 15, 2002 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato:NOV.MI) (ISIN: IT0001482444) today announced that it has acquired full rights to the anti-angiogenic...